Inverness Acquisition Of Unipath Could Lead To New Cardiology Diagnostics
This article was originally published in The Tan Sheet
Executive Summary
Inverness Medical Innovations' acquisition of home pregnancy test manufacturer Unipath and its immunodiagnostic technologies could lead to new self-diagnostic tools in the cardiology arena
You may also be interested in...
Inverness cements IVC acquisition
Device firm completes purchase of supplement marketer IVC Industries March 19; transaction will provide Inverness with "additional production and distribution resources," as well as private label presence, firm says (1"The Tan Sheet" Dec. 24, 2001, p. 7). Original agreement, announced Sept. 21, was amended in January to allow IVC stockholders to receive $2.50 in cash for each share of stock rather than exchange for shares of Inverness stock. For fourth quarter ending Dec. 31, Inverness recorded $13.7 mil. in sales, up 11.2% from last year; FY 2001 sales dipped 3.3% to $49.4 mil., firm says. Net losses were $25.9 mil and $24.7 mil. for Q4 and the year, respectively, attributable to Unipath acquisition, split-off/merger with J&J...
Inverness To Add Private Label Supplement Business, Facilities With IVC Buy
Inverness Medical Technology will add a private label component to its small branded dietary supplement business with its planned acquisition of IVC Industries. Under a letter of intent signed Sept. 21, Inverness has agreed to acquire IVC pending resolution of several issues.
Unilever Exiting OTC Diagnostics Business With Unipath Sale
Unilever plans to divest its nearly $90 mil. Unipath women's health diagnostics business, which includes the Clearblue line of home pregnancy test kits, to focus on selected consumer brands, the firm said June 19.